-+ 0.00%
-+ 0.00%
-+ 0.00%

HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

Benzinga·09/10/2026 13:55:33
Listen to the news
HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.